Integral Health Asset Management LLC Invests $13.86 Million in Edwards Lifesciences Co. (NYSE:EW)

Integral Health Asset Management LLC bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 150,000 shares of the medical research company’s stock, valued at approximately $13,856,000. Edwards Lifesciences comprises about 1.3% of Integral Health Asset Management LLC’s portfolio, making the stock its 23rd largest holding.

Other hedge funds have also modified their holdings of the company. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at $28,000. Crewe Advisors LLC purchased a new position in Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences in the 2nd quarter valued at $29,000. Riverview Trust Co purchased a new position in Edwards Lifesciences in the 1st quarter valued at $34,000. Finally, Pingora Partners LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at $38,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Citigroup raised their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Evercore ISI reduced their target price on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a report on Thursday, July 25th. Oppenheimer reissued an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their target price for the company from $105.00 to $75.00 in a report on Thursday, July 25th. Finally, Stifel Nicolaus reduced their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Sixteen investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.82.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $4,378,659.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $4,378,659.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,250 shares of company stock worth $1,218,138. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Down 0.6 %

EW opened at $66.83 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The stock has a market capitalization of $40.27 billion, a price-to-earnings ratio of 28.81, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. The business has a 50-day moving average of $69.89 and a two-hundred day moving average of $82.80. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the previous year, the business earned $0.66 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, research analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.